Key result
Recent advances in mitral valve disease management include updated 2017 guidelines, new pathophysiological insights from 3D imaging, and the expanding role of transcatheter procedures.
Why the study?
New technologies allowing intervention in previously untreatable patients have driven a substantial rise in mitral valve publications, particularly regarding mitral regurgitation and interventions.
This review highlights recent advances in mitral valve disease management, emphasizing the undertreatment of significant mitral regurgitation and summarizing key changes in the 2017 AHA/ACC and ESC guidelines.
May prompt reevaluation of mitral valve treatment algorithms; leaves open prospective assessment of transcatheter outcomes.
Interest in the mitral valve has increased over the past few years with the development of new technologies that allow intervention in patients previously deemed too ill for treatment. This increased attention has resulted in a significant increase in publications on the mitral valve, the majority of which focus on mitral regurgitation and mitral valve surgery/intervention. The focus of this review is on publications in the past few years that offer additional insights into our understanding and management of mitral valve disease and specifically mitral regurgitation. It will discuss mitral valve anatomy, epidemiology of mitral valve disease, changes in the 2017 management guidelines, management of mitral bioprosthetic valves, transcatheter mitral valve procedures and the repair of rheumatic valves.
No takes yet. Share an insight, caveat, or question.
Wendy Tsang (2019) conducted a review in Mitral valve disease. Recent advances in mitral valve disease management include updated 2017 guidelines, new pathophysiological insights from 3D imaging, and the expanding role of transcatheter procedures.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: